Tech Company Financing Transactions
TargeGen Funding Round
On 1/13/2004, TargeGen secured $30 million in Series B financing from Enterprise Partners Venture Capital and Forward Ventures.
Transaction Overview
Company Name
Announced On
1/13/2004
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series B
Proceeds Purpose
This financing is expected to allow us to take our first two drug leads into human clinical trials and accelerate our other discovery and development programs.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
9380 Judicial Drive
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
TargeGen, Inc. is a privately held, vascular biology-focused, biopharmaceutical company based in San Diego, CA. TargeGen is developing novel small molecule therapeutics to treat cancer and ischemic diseases (heart attack, stroke) by targeting certain biochemical processes associated with disease related changes in vascular permeability and vascular proliferation.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Ulrich
Chief Financial Officer
Wood Erwin
Vice President
Jolene Shorr
VP - Regulatory Affairs
David McClure
Browse more venture capital transactions:
Prev: 1/13/2004: Carbon Design Systems venture capital transaction
Next: 1/13/2004: Sana Security venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs